A new combined vaccine against measles, mumps, rubella and varicella in India

被引：0
作者：
Nitin Shah
Raunak Parikh
Giacomo Casabona
Shafi Kolhapure
机构：
[1] PD Hinduja National Hospital,
[2] PD Hinduja National Hospital,undefined
[3] GSK,undefined
[4] Dr Annie Besant Rd,undefined
[5] PD Hinduja National Hospital,undefined
[6] GSK,undefined
来源：
Indian Pediatrics | 2017年 / 54卷
关键词：
Chicken pox; Measles-Mumps-Rubella vaccine; Prevention; Varicella;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A quadrivalent MMRV (measles-mumps-rubella-varicella) combination vaccine has recently been launched in India. This vaccine is highly immunogenic, with seroconversion rates against all antigens reaching 96.6-100% at 42 to 56 days after the second vaccine dose in unvaccinated children or in those previously vaccinated with MMR+/-V. Two doses efficacy, against all varicella is 94.1% and effectiveness reaches 91%. The most frequent solicited local adverse event after MMRV vaccine is redness, and fever is the most common solicited general symptom. Higher rates of fever and febrile convulsions compared to MMR+/-V have been reported when used as first dose but not when used as the second of a measles containing vaccine, irrespective of age of the second dose.
引用
收藏
页码：1041 / 1046
页数：5
相关论文
共 107 条
  • [1] Mathew JL(2009)Evidence-based options to improve routine immunization Indian Pediatr. 46 993-6
  • [2] Marshall GS(2007)Use of combination vaccines is associated with improved coverage rates Pediatr Infect Dis J. 26 496-500
  • [3] Happe LE(2015)Combination measles-mumps-rubella-varicella vaccine in healthy children: A systematic review and meta-analysis of immunogenicity and safety Medicine. 94 e1721-11
  • [4] Lunacsek OE(2009)A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): Immunogenicity and safety profile Vaccine. 27 6504-33
  • [5] Szymanski MD(2010)Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months Eur J Pediatr. 169 925-30
  • [6] Woods CR(2008)Immunogenicity and safety assessments after one and two doses of a refrigeratorstable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life Pediatr Infect Dis J. 27 724-8
  • [7] Zahn M(2006)Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children Pediatr Infect Dis J. 25 12-70
  • [8] Ma SJ(2012)Antibody persistence for 3 years following two doses of tetravalent measles-mumpsrubella-varicella vaccine in healthy children Eur J Pediatr. 171 463-6
  • [9] Li X(2009)Safety and immunogenicity of a measlesmumps-rubella-varicella vaccine given as a second dose in children up to six years of age Vaccine. 27 2701-53
  • [10] Xiong YQ(2009)Immunogenicity and safety of measles-mumpsrubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine Vaccine. 27 446-24
12345678910